Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-569-5 | CAS number: 108-29-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- Data published in 1973
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- publication
- Title:
- Structural requirements for centrally acting drugs I
- Author:
- Lien E. J., Tong G.L., Chou J. T., Lien L. L.
- Year:
- 1 973
- Bibliographic source:
- Journal of Pharmaceutical Sciences 62.2 (1973): 246-250.
Materials and methods
- Objective of study:
- distribution
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- - Principle of test: Comparison of CNS activity of different lactones in mice.
- Short description of test conditions: In a study in mice, the CNS activity of five different lactones was investigated. Groups of six mice, three males and three females weighting 17-27 g, were injected intraperitoneally with an aqueous solution of the test item. Signs of CNS activity or other changes were observed continuously for 2 hours and then at regular intervals for 2 days.
- Parameters analysed / observed: Cage side observations, neurological parameters (righting reflex, paralysis of the hind legs). - GLP compliance:
- no
Test material
- Reference substance name:
- γ-valerolactone
- EC Number:
- 203-569-5
- EC Name:
- γ-valerolactone
- Cas Number:
- 108-29-2
- Molecular formula:
- C5H8O2
- IUPAC Name:
- 5-methyloxolan-2-one
Constituent 1
- Specific details on test material used for the study:
- Not specified
- Radiolabelling:
- no
Test animals
- Species:
- mouse
- Strain:
- not specified
- Details on species / strain selection:
- Not specified
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 17-27 g
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- water
- Details on exposure:
- Not specified
- Duration and frequency of treatment / exposure:
- Single treatment
Doses / concentrationsopen allclose all
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Dose / conc.:
- 2 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose / concentration:
- 3 males and 3 females
- Control animals:
- not specified
- Positive control reference chemical:
- Not specified
- Details on study design:
- Not specified
- Details on dosing and sampling:
- Not specified
- Statistics:
- Not specified
Results and discussion
Main ADME resultsopen allclose all
- Type:
- metabolism
- Results:
- The test item in alkaline medium showed no appreciable hydrolysis by liver ersterase preparations that were reactive toward methyl butyrate.
- Type:
- distribution
- Results:
- - decreased CNS depressant activity of lactones when a methyl group is attached to the α or γ position
- no loss of righting reflex at 2000 mg/kg bw after treatment with the test item
- potential local anesthetic activity on the peripheral nervous system
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Not specified
- Details on distribution in tissues:
- Partial paralysis of the hind legs was observed at 1000 mg/kg bw, indicating local anesthetic activity on the peripheral nervous system. Mild sedation at 1000 mg/kg bw, indicating a decreased CNS activity compared to γ-butyrolactone, although the lipophilic character is increased.
Metabolite characterisation studies
- Metabolites identified:
- not specified
- Details on metabolites:
- Not specified
Enzymatic activity
- Enzymatic activity measured:
- Not specified
Bioaccessibility (or Bioavailability)
- Bioaccessibility (or Bioavailability) testing results:
- Not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.